Praziquantel and factor H recruitment differentially affect the susceptibility of Schistosoma mansoni to complement-mediated damage

Front Immunol. 2024 Nov 12:15:1474358. doi: 10.3389/fimmu.2024.1474358. eCollection 2024.

Abstract

Background: Schistosomes are highly efficient evaders of human immunity, as evident by their ability to survive in human blood for years. How they protect themselves against the constant attack by a key element of innate immunity, the complement system, has remained unclear. In this study, new light is shed on the interaction between distinct life-cycle stages of Schistosoma mansoni and the human complement system.

Results: We demonstrate that schistosomula, the young stage assumed immediately after cercaria penetration of the skin, are extremely vulnerable towards complement-mediated killing as only 10-20% survive. The survival rate increases to 70% already within 30 minutes and reaches close to 100% within two hours. Pathway-specific complement inhibitors revealed the alternative pathway of complement activation as the main contributor to killing and damage of the schistosomula. Moreover, the complement regulator factor H is recruited by the schistosomula in this early stage to evade killing. Surviving parasites appear fully viable despite the ongoing complement attack, as demonstrated by the deposition of C3 fragments. However, when exposed to the widely used schistocidal drug praziquantel, the vulnerability of 24 h-old schistosomula towards complement-mediated killing is notably increased; no such effect was observed for mefloquine or oxamniquine. Similar to the younger life-cycle stages, adult worms remain under complement attack. C3 fragments were found all over the outer surface (tegument), deposited mostly on the ridges and not on the tubercles.

Conclusion: The recruitment of factor H merits more detailed studies that pinpoint the molecules involved and elucidate the novel possibilities to intercept the uncovered immune evasion therapeutically. That praziquantel and complement work in synergy is surprising and may in the future result in enhanced understanding of the drug's mechanism of action.

Keywords: Schistosoma mansoni; complement; complement evasion; complement factor H; host-pathogen interactions; praziquantel.

MeSH terms

  • Animals
  • Anthelmintics / pharmacology
  • Anthelmintics / therapeutic use
  • Complement Activation / drug effects
  • Complement Factor H* / immunology
  • Complement Factor H* / metabolism
  • Complement System Proteins / immunology
  • Complement System Proteins / metabolism
  • Disease Susceptibility
  • Host-Parasite Interactions / immunology
  • Humans
  • Life Cycle Stages
  • Mice
  • Praziquantel* / pharmacology
  • Schistosoma mansoni* / immunology
  • Schistosomiasis mansoni / immunology
  • Schistosomiasis mansoni / parasitology

Substances

  • Complement Factor H
  • Praziquantel
  • Complement System Proteins
  • Anthelmintics

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The research described in this manuscript was funded via a KNAW Ter Meulen Grant from the KNAW Medical Sciences Fund (Royal Netherlands Academy of Arts & Sciences and via a grant from the Excellent Junior Researcher Fund (University of Basel), both awarded to AB, and the Swiss National Science Foundation (No. 320030_175585, awarded to JK, No. CRSK-3_196744, awarded to RP, and No. 31003A_176104 and 310030_219969, awarded to DR). Grant K135289 from the National Research Development and Innovation Office (Hungarian Scientific Research Fund) was provided to GP. Grant SCHM 3018/4-1 from the Deutsche Forschungsgemeinschaft (DFG) was awarded to CS.